189 related articles for article (PubMed ID: 34757194)
1. NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.
Wang Y; Jin J; Li Y; Zhou Q; Yao R; Wu Z; Hu H; Fang Z; Dong S; Cai Q; Hu S; Liu B
Transl Res; 2022 Feb; 240():64-86. PubMed ID: 34757194
[TBL] [Abstract][Full Text] [Related]
2. A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity.
Zhao Q; Zhang W; Ning Z; Zhuang X; Lu H; Liang J; Li J; Zhang Y; Dong Y; Zhang Y; Zhang S; Liu S; Liu B
PLoS One; 2014; 9(3):e93103. PubMed ID: 24671154
[TBL] [Abstract][Full Text] [Related]
3. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
Zhang J; Guo Y; Fang H; Guo X; Zhao L
Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
[TBL] [Abstract][Full Text] [Related]
5. UV Light-inactivated HSV-1 Stimulates Natural Killer Cell-induced Killing of Prostate Cancer Cells.
Samudio I; Hofs E; Cho B; Li M; Bolduc K; Bu L; Liu G; Lam V; Rennie P; Jia W; Elisia I; Krystal G
J Immunother; 2019 Jun; 42(5):162-174. PubMed ID: 30933043
[TBL] [Abstract][Full Text] [Related]
6. UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells.
Samudio I; Rezvani K; Shaim H; Hofs E; Ngom M; Bu L; Liu G; Lee JT; Imren S; Lam V; Poon GF; Ghaedi M; Takei F; Humphries K; Jia W; Krystal G
Blood; 2016 May; 127(21):2575-86. PubMed ID: 26941401
[TBL] [Abstract][Full Text] [Related]
7. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology.
Cai L; Hu H; Duan H; Li Y; Zou Z; Luo K; Zhang Z; Yang J; Jin J; Chen Y; Ke Z; Fang Z; Liu Q; Hong X; Hu S; Liu B
J Med Virol; 2020 Dec; 92(12):3617-3627. PubMed ID: 31994741
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Herpes Simplex Virus Type 2 Can Effectively Inhibit Colorectal Cancer Liver Metastasis by Modulating the Immune Status in the Tumor Microenvironment and Inducing Specific Antitumor Immunity.
Zhang W; Zeng B; Hu X; Zou L; Liang J; Song Y; Liu B; Liu S
Hum Gene Ther; 2021 Feb; 32(3-4):203-215. PubMed ID: 33176492
[TBL] [Abstract][Full Text] [Related]
9. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
Kamiya T; Seow SV; Wong D; Robinson M; Campana D
J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
[TBL] [Abstract][Full Text] [Related]
10. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity.
Zhang W; Hu X; Liang J; Zhu Y; Zeng B; Feng L; Zhao C; Liu S; Liu B; Zhang K
Mol Ther Oncolytics; 2020 Mar; 16():158-171. PubMed ID: 32055679
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells.
Lo Monaco E; Tremante E; Cerboni C; Melucci E; Sibilio L; Zingoni A; Nicotra MR; Natali PG; Giacomini P
Neoplasia; 2011 Sep; 13(9):822-30. PubMed ID: 21969815
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo.
Yin L; Zhao C; Han J; Li Z; Zhen Y; Xiao R; Xu Z; Sun Y
Ther Clin Risk Manag; 2017; 13():117-130. PubMed ID: 28223815
[TBL] [Abstract][Full Text] [Related]
13. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
14. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.
Alvarez-Breckenridge CA; Yu J; Price R; Wei M; Wang Y; Nowicki MO; Ha YP; Bergin S; Hwang C; Fernandez SA; Kaur B; Caligiuri MA; Chiocca EA
J Virol; 2012 Apr; 86(8):4566-77. PubMed ID: 22318143
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
16. Proteomic comparison of 3D and 2D glioma models reveals increased HLA-E expression in 3D models is associated with resistance to NK cell-mediated cytotoxicity.
He W; Kuang Y; Xing X; Simpson RJ; Huang H; Yang T; Chen J; Yang L; Liu E; He W; Gu J
J Proteome Res; 2014 May; 13(5):2272-81. PubMed ID: 24742303
[TBL] [Abstract][Full Text] [Related]
17. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
18. Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models.
Yang H; Peng T; Li J; Wang Y; Zhang W; Zhang P; Peng S; Du T; Li Y; Yan Q; Liu B
Gene Ther; 2016 May; 23(5):450-9. PubMed ID: 26871935
[TBL] [Abstract][Full Text] [Related]
19. A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy.
Hu H; Zhang S; Cai L; Duan H; Li Y; Yang J; Wang Y; Liu B; Dong S; Fang Z; Liu B
Virol J; 2022 Apr; 19(1):74. PubMed ID: 35459242
[TBL] [Abstract][Full Text] [Related]
20. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
